Amit Achhra, MPH, PhD, MD
Assistant Professor of Medicine (Infectious Diseases)Cards
About
Research
Publications
2025
Combined Use of Ibalizumab and Lenacapavir for the Treatment of Multidrug-resistant HIV-1: A Case Series
Rolle C, Achhra A, Harbison C, Finkel D, Lucasti C, Martorell C, McClendon T, Slim J. Combined Use of Ibalizumab and Lenacapavir for the Treatment of Multidrug-resistant HIV-1: A Case Series. Clinical Infectious Diseases 2025, 82: e534-e540. PMID: 41187020, PMCID: PMC13017887, DOI: 10.1093/cid/ciaf597.Peer-Reviewed Original ResearchHuman immunodeficiency virusCD4+ countViral loadMultidrug resistanceMultidrug-resistant human immunodeficiency virusStrains of human immunodeficiency virusMultidrug-resistant HIV-1Weeks of treatment initiationHuman immunodeficiency virus-1HIV-1 RNAAcquired multidrug resistanceImmunodeficiency virus-1Retrospective observational studyClinically significant reductionBackground regimenSalvage therapyTreatment-experiencedImmunodeficiency virusLenacapavirCase seriesTherapeutic optionsTreatment initiationMedical chartsHIV-1PWH
2024
Corrigendum to “Long-term impact of immediate versus deferred antiretroviral therapy on kidney health in people with HIV.” Kidney International 2024;106:136–144
Pelchen-Matthews A, Mocroft A, Ryom L, Ross M, Sharma S, Coca S, Achhra A, Cornell E, Tracy R, Phillips A, Alonso M, Toulomi G, Agan B, Medland N, Wyatt C, Group I. Corrigendum to “Long-term impact of immediate versus deferred antiretroviral therapy on kidney health in people with HIV.” Kidney International 2024;106:136–144. Kidney International 2024, 106: 1196. PMID: 39577998, PMCID: PMC11819966, DOI: 10.1016/j.kint.2024.10.002.Commentaries, Editorials and LettersFive-Year Evaluation of an Anal Cancer Screening Program in Men Who Have Sex With Men With HIV at 2 Academic Center Clinics
Achhra A, Chan E, Applebaum S, Guerrero M, Hao R, Pantel H, Virata M, Fikrig M, Barakat L. Five-Year Evaluation of an Anal Cancer Screening Program in Men Who Have Sex With Men With HIV at 2 Academic Center Clinics. Clinical Infectious Diseases 2024, 80: 1133-1138. PMID: 39492696, DOI: 10.1093/cid/ciae541.Peer-Reviewed Original ResearchHigh-Resolution AnoscopyAnal cytologyAnal cancer screening programAbnormal anal cytologyAcademic HIV clinicSquamous cell carcinomaRetrospective chart reviewHistory of smokingEligible populationCancer screening programDetecting HSILAbnormal cytologyTriage testCell carcinomaHIV clinicChart reviewOlder age groupsHSILFollow-upCytologyScreening programScreening testCenter clinicIncreasing ageEligible individualsLong-term impact of immediate versus deferred antiretroviral therapy on kidney health in people with HIV
Pelchen-Matthews A, Mocroft A, Ryom L, Ross M, Sharma S, Coca S, Achhra A, Cornell E, Tracy R, Phillips A, Alonso M, Toulomi G, Agan B, Medland N, Wyatt C, Group I. Long-term impact of immediate versus deferred antiretroviral therapy on kidney health in people with HIV. Kidney International 2024, 106: 136-144. PMID: 38697479, PMCID: PMC11193627, DOI: 10.1016/j.kint.2024.04.010.Peer-Reviewed Original ResearchHuman immunodeficiency virusUrine albumin/creatinine ratioDeferred antiretroviral therapyChronic kidney diseaseStrategic Timing of AntiRetroviral TreatmentAntiretroviral therapyNo significant differenceTreatment armsFollow-upAnnual rate of eGFR declineRate of eGFR declineTiming of AntiRetroviral TreatmentEarly ARTART-naive adultsCD4 cell countImmediate antiretroviral therapySignificant differenceKidney-related deathLong-term safetyKidney healthStandard of careComprehensive follow-upImmunodeficiency virusAlbumin/creatinine ratioEGFR declineAcute Hepatitis Due to Primary Human Immunodeficiency Virus Infection
Open Forum Infectious Diseases, ofae170, https://doi.org/10.1093/ofid/ofae170 Published: 22 March 2024Peer-Reviewed Case Reports and Technical NotesAcute Hepatitis due to Primary Human Immunodeficiency Virus Infection
Elliott E, Smith D, Lipscomb J, Banini B, Meurer L, Vanderford T, Johnson J, Jain D, Achhra A. Acute Hepatitis due to Primary Human Immunodeficiency Virus Infection. Open Forum Infectious Diseases 2024, 11: ofae170. PMID: 38585186, PMCID: PMC10996125, DOI: 10.1093/ofid/ofae170.Peer-Reviewed Original ResearchHuman immunodeficiency virusHuman immunodeficiency virus infectionAcute hepatitisPrimary human immunodeficiency virus infectionConsistent with acute hepatitisPrimary human immunodeficiency virusHuman immunodeficiency virus p24 antigenAcute retroviral syndromeImmunodeficiency virus infectionSevere acute hepatitisHIV proviral DNAAcute liver diseaseP24 antigenImmunodeficiency virusLaboratory abnormalitiesSystemic manifestationsRare caseLiver diseaseProviral DNAVirus infectionLiver histopathologyHepatitisCell compartmentParenchymal cellsLiver tissue
2022
Contrasting Cases of HIV Vasculopathy Associated Fusiform Aneurysms
Kyle K, Maher M, Achhra A, Venna N. Contrasting Cases of HIV Vasculopathy Associated Fusiform Aneurysms. The Neurohospitalist 2022, 13: 69-73. PMID: 36531848, PMCID: PMC9755620, DOI: 10.1177/19418744221122863.Peer-Reviewed Original ResearchHuman immunodeficiency virusProgressive multifocal leukoencephalopathyFusiform aneurysmsAntiretroviral therapy adherenceAcquired Immunodeficiency SyndromeSpectrum of severityDevelopment of aneurysmsCerebral toxoplasmosisMultifocal leukoencephalopathyClinical courseImmunodeficiency syndromeImmunodeficiency virusTherapy adherenceVessel occlusionAneurysm formationAneurysm thrombosisIntracranial fusiform aneurysmsAneurysmsCerebral aneurysmsNine monthsFirst caseCase twoVasculopathyMoyamoyaLeukoencephalopathy
2015
O21.3 Pre-therapy inflammation/coagulation activation and long-term cd4 response to antiretroviral therapy
Achhra A, Phillips A, Emery S, MacArthur R, Furrer H, De Wit S, Losso M, Law M. O21.3 Pre-therapy inflammation/coagulation activation and long-term cd4 response to antiretroviral therapy. Sexually Transmitted Infections 2015, 91: a73.1-a73. DOI: 10.1136/sextrans-2015-052270.195.Peer-Reviewed Original ResearchShort‐term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the D:A:D study
Achhra A, Mocroft A, Reiss P, Sabin C, Ryom L, de Wit S, Smith C, Monforte A, Phillips A, Weber R, Lundgren J, Law, Group T. Short‐term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the D:A:D study. HIV Medicine 2015, 17: 255-268. PMID: 26216031, DOI: 10.1111/hiv.12294.Peer-Reviewed Original ResearchConceptsBody mass indexIncidence rate ratiosCardiovascular diseaseART initiationBMI categoriesHistory of CVDAntiretroviral therapy initiationRisk of diabetesTreatment-naïve individualsMain exposure variableLong-term riskPoisson regression modelsDiabetes eventsCD4 countCVD eventsTherapy initiationAdverse eventsCardiometabolic outcomesCohort studyMass indexRisk factorsSubsequent riskNormal rangeDiabetesExposure variablesPre‐therapy inflammation and coagulation activation and long‐term CD4 count responses to the initiation of antiretroviral therapy
Achhra A, Phillips A, Emery S, MacArthur R, Furrer H, De Wit S, Losso M, Law, groups I. Pre‐therapy inflammation and coagulation activation and long‐term CD4 count responses to the initiation of antiretroviral therapy. HIV Medicine 2015, 16: 449-454. PMID: 25959989, PMCID: PMC5676307, DOI: 10.1111/hiv.12258.Peer-Reviewed Original ResearchConceptsCD4 count responseBaseline CD4 countC-reactive proteinCD4 countART initiationClinical outcomesCoagulation activationBiomarker levelsInterleukin-6Therapy trialsMedian baseline CD4 countAntiretroviral Therapy (SMART) trialFirst-line ARTInflammatory marker levelsHIV-positive individualsLong-term CD4CD4 count measurementCD4 responseART-naïveCent of individualsStudy armsD-dimerCount responseMean ageMarker levels
Academic Achievements & Community Involvement
Clinical Care
Overview
Amit Achhra, MD, PhD, specializes in infectious diseases, with a clinical interest in HIV primary care, managing cases of HIV with complex resistance history, sexually transmitted infections (STIs), COVID-19 therapeutics, and general infectious diseases.
Dr. Achhra trains residents and fellows in his role as an assistant professor of medicine (infectious diseases) at Yale School of Medicine. His research focuses on the implementation of HIV care strategies, STI research, and clinical trials in HIV and COVID-19.
Dr. Achhra completed his medical training at K J Somaiya Medical College, Maharashtra University of Health Sciences in India and earned his doctoral degree from the Kirby Institute/University of New South Wales in Australia. He completed his internal medicine residency at NewYork-Presbyterian/Weill Cornell Medical Center and a fellowship in infectious diseases/HIV at Massachusetts General Hospital and Brigham and Women's Hospital, Harvard University.
Clinical Specialties
Infectious Diseases; HIV & AIDs Medicine
Fact Sheets
Human Immunodeficiency Virus (HIV)
Learn More on Yale MedicineSepsis
Learn More on Yale MedicinePediatric Sepsis
Learn More on Yale MedicineParasitic Diseases
Learn More on Yale Medicine
Yale Medicine News
News
News
- July 26, 2024Source: Healthline
Twice-Yearly Shot Offers 100% HIV Protection, Study Finds
- July 10, 2024
Faculty and Trainees Recognized for Outstanding Teaching During Internal Medicine Primary Care Residency Graduation
- February 23, 2024
Department of Internal Medicine Promotions and Appointments (February 2024)
- March 08, 2023
Faculty Network Spotlight: NGN
Get In Touch
Contacts
Email
Appointment Number
Administrative Support
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.